Medicaid Coverage of Medications for the Treatment of Opioid Use Disorder

In Connecticut between 2008-2012, persons enrolled in substance use treatment programs that prescribed methadone increased 32.9%. In 2012 in Connecticut, 24.4% of persons aged 12 and older who met criteria for having a drug use disorder received treatment.

State Benefits at a Glance

Methadone

Connecticut Medicaid covers methadone under Fee-For-Service (FFS) plans. In order to receive coverage for methadone for the treatment of opioid use disorder, federal law mandates that patients are enrolled in, or have documented proof of, substance use disorder (SUD) counseling. The state of Connecticut covers methadone as a medical benefit under FFS plans.

Buprenorphine/Naloxone film (Suboxone ®), Buprenorphine/Naloxone tablets (generic), Buprenorphine/Naloxone tablets (Zubsolv ®c) and Buprenorphine tablets (generic).

Medication Limitations

Connecticut Medicaid covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets under FFS plans with the following limitations:

- Patients are not required to be enrolled in, or have documented proof of, SUD* counseling in order to receive coverage for Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets.
- Connecticut covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets as a pharmacy benefit under FFS plans.
- Zubsolv appears on Connecticut Medicaid’s Preferred Drug List.
- In most cases, Zubsolv is subject to the same prior authorization requirements as the surveyed buprenorphine products.

Only Suboxone is listed on Connecticut’s preferred drug list for FFS plans. No information was provided about coverage for use in specialty outpatient treatment Programs (OTPs) or accredited outpatient narcotic treatment programs (NTPs). Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets are covered in physician’s offices under FFS plans.

Data from SAMHSA’s State and Metro Reports accessed http://www.samhsa.gov/data/States_In_Brief_Reports.aspx
β Data as of spring 2014.
° Zubsolv was not included in the original survey, as the medication was not FDA approved until fall of 2013. This summary reflects only information related to Preferred Drug List (PDL) and formulary inclusion obtained from pharmacy and State websites.
*In Connecticut, Substance Use Disorder (SUD) counseling is a covered Medicaid benefit under FFS plans.
Injectable Naltrexone (VIVITROL®)

Connecticut Medicaid covers injectable naltrexone (Vivitrol®) under FFS plans. Patients do not need to be enrolled in, or have documented proof of SUD* counseling for Vivitrol coverage.

- Vivitrol is listed as a pharmacy benefit under FFS plans.
- Vivitrol is not listed on the state’s preferred drug list under FFS plans.

No information was provided about coverage of Vivitrol in OTP or NTP settings, however Vivitrol is covered in physician’s offices under FFS plans. No information was provided about Managed Care plans.

Currently, Connecticut is considering phase-based methadone treatment payments. Under this plan, patients would pay the current rate for the first year of therapy, a reduced rate for the second year, and further reduced rates for the third year and beyond.

Medicaid Benefits for Treatment of Opioid Dependence Nationwide

Number of Medications Covered under Fee-For-Service Medicaid Plans By State

Data collected by the Avisa Group and Treatment Research Institute 2013-2014